Jolie Ringash

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5818051/publications.pdf

Version: 2024-02-01

224 papers

11,848 citations

57 h-index

24978

30848 102 g-index

224 all docs

224 docs citations

times ranked

224

12866 citing authors

#	Article	IF	CITATIONS
1	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG) Tj ETQq1 1	l 0.784314	1 rgBT /Over
2	Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2013, 31, 1631-1639.	0.8	672
3	Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis. Journal of Clinical Oncology, 2013, 31, 543-550.	0.8	551
4	Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases. Journal of Clinical Oncology, 2009, 27, 1585-1591.	0.8	424
5	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus–Related Oropharyngeal Carcinomas. Journal of Clinical Oncology, 2015, 33, 836-845.	0.8	345
6	Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. Journal of Clinical Oncology, 2010, 28, 2989-2995.	0.8	339
7	Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma. Journal of Clinical Oncology, 2009, 27, 6213-6221.	0.8	289
8	Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncology, 2013, 49, 79-85.	0.8	239
9	Interpreting clinically significant changes in patient-reported outcomes. Cancer, 2007, 110, 196-202.	2.0	237
10	Atypical Clinical Behavior of p16-Confirmed HPV-Related Oropharyngeal Squamous Cell Carcinoma Treated With Radical Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 276-283.	0.4	207
11	Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival. Journal of the National Cancer Institute, 2011, 103, 1851-1858.	3.0	196
12	Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiotherapy and Oncology, 2014, 111, 412-417.	0.3	177
13	A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer, 2014, 120, 302-311.	2.0	168
14	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiotherapy and Oncology, 2012, 103, 49-56.	0.3	167
15	A structured review of quality of life instruments for head and neck cancer patients. Head and Neck, 2001, 23, 201-213.	0.9	165
16	Survivorship and Quality of Life in Head and Neck Cancer. Journal of Clinical Oncology, 2015, 33, 3322-3327.	0.8	162
17	Error in the delivery of radiation therapy: Results of a quality assurance review. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1590-1595.	0.4	145
18	Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Supportive Care in Cancer, 2011, 19, 1753-1760.	1.0	133

#	Article	IF	CITATIONS
19	Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer, 2015, 121, 545-555.	2.0	133
20	Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiotherapy and Oncology, 2008, 89, 287-291.	0.3	132
21	Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Quality of Life Research, 2011, 20, 653-664.	1.5	123
22	A systematic review of quality of life in head and neck cancer treated with surgery with or without adjuvant treatment. Oral Oncology, 2015, 51, 888-900.	0.8	123
23	Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. Journal of Clinical Oncology, 2013, 31. 2477-2484.	0.8	122
24	Intraobserver and Interobserver Variability in GTV Delineation on FDG-PET-CT Images of Head and Neck Cancers. International Journal of Radiation Oncology Biology Physics, 2007, 68, 763-770.	0.4	121
25	Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. International Journal of Radiation Oncology Biology Physics, 2006, 64, 709-716.	0.4	106
26	Point-of-care outcome assessment in the cancer clinic: Audit of data quality. Radiotherapy and Oncology, 2010, 95, 339-343.	0.3	105
27	The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. European Journal of Cancer, 2015, 51, 2808-2819.	1.3	105
28	Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 94, 580-587.	0.4	103
29	Temporal Nodal Regression and Regional Control After Primary Radiation Therapy for N2-N3 Head-and-Neck Cancer Stratified by HPV Status. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1078-1085.	0.4	100
30	Interfraction and Respiratory Organ Motion During Conformal Radiotherapy in Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 53-59.	0.4	99
31	Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensityâ€modulated radiotherapy. Cancer, 2017, 123, 3691-3700.	2.0	99
32	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 340-352.	0.4	99
33	Staging and surgical approaches in gastric cancer: A systematic review. Cancer Treatment Reviews, 2018, 63, 104-115.	3.4	98
34	Head and Neck Cancer Survivorship: Learning the Needs, Meeting the Needs. Seminars in Radiation Oncology, 2018, 28, 64-74.	1.0	97
35	IMRT for adjuvant radiation in gastric cancer: A preferred plan?. International Journal of Radiation Oncology Biology Physics, 2005, 63, 732-738.	0.4	94
36	Phase II Trial of Palliative Radiotherapy for Hepatocellular Carcinoma and Liver Metastases. Journal of Clinical Oncology, 2013, 31, 3980-3986.	0.8	94

#	Article	IF	CITATIONS
37	Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: A systematic review. Oral Oncology, 2014, 50, 254-262.	0.8	94
38	Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 939-946.	0.4	94
39	A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2002, 54, 9-13.	0.4	93
40	Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head and Neck, 2008, 30, 1607-1614.	0.9	93
41	Prospective Evaluation of Acute Toxicity and Quality of Life After IMRT and Concurrent Chemotherapy for Anal Canal and Perianal Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 587-594.	0.4	88
42	Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 119-128.	0.7	83
43	Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. Head and Neck, 2016, 38, E820-6.	0.9	82
44	Primary radical external beam radiotherapy of rectal adenocarcinoma: Long term outcome of 271 patients. Radiotherapy and Oncology, 2005, 77, 126-132.	0.3	81
45	Cognitive Functioning After Radiotherapy or Chemoradiotherapy for Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 126-134.	0.4	78
46	Patterns of Care in Elderly Head-and-Neck Cancer Radiation Oncology Patients: A Single-Center Cohort Study. International Journal of Radiation Oncology Biology Physics, 2011, 79, 46-51.	0.4	77
47	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. European Journal of Cancer, 2016, 67, 174-182.	1.3	75
48	Dysphagia Treatment for Patients With Head and Neck Cancer Undergoing Radiation Therapy: A Meta-analysis Review. International Journal of Radiation Oncology Biology Physics, 2018, 101, 421-444.	0.4	71
49	Interpreting differences in quality of life: The FACT-H&N in laryngeal cancer patients. Quality of Life Research, 2004, 13, 725-733.	1.5	69
50	Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 99, 388-395.	0.4	68
51	Effect of Concurrent High-Dose Cisplatin Chemotherapy and Conformal Radiotherapy on Cervical Esophageal Cancer Survival. International Journal of Radiation Oncology Biology Physics, 2008, 71, 735-740.	0.4	66
52	Prevalence and nature of survivorship needs in patients with head and neck cancer. Head and Neck, 2016, 38, 1097-1103.	0.9	64
53	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. JAMA Oncology, 2017, 3, 220.	3.4	64
54	Cone-Beam CT Assessment of Interfraction and Intrafraction Setup Error of Two Head-and-Neck Cancer Thermoplastic Masks. International Journal of Radiation Oncology Biology Physics, 2010, 76, 949-955.	0.4	63

#	Article	IF	CITATIONS
55	Prospective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 16-25.	0.4	63
56	Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25ÂYears Later. International Journal of Radiation Oncology Biology Physics, 2017, 98, 159-169.	0.4	61
57	Local excision and postoperative radiotherapy for distal rectal cancer. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1309-1316.	0.4	60
58	Head and Neck Cancer Survivorship Care: A Review of the Current Guidelines and Remaining Unmet Needs. Current Treatment Options in Oncology, 2018, 19, 44.	1.3	58
59	Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1107-1116.	0.4	57
60	Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncology, 2016, 54, 75-80.	0.8	56
61	Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1403-1407.	0.4	55
62	Patient preferences for oropharyngeal cancer treatment deâ€escalation. Head and Neck, 2013, 35, 151-159.	0.9	55
63	Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus–Mediated Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1017-1027.	0.4	50
64	Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure. Oral Oncology, 2013, 49, 255-260.	0.8	49
65	Stage-Specific Effect of Adjuvant Therapy Following Gastric Cancer Resection: a Population-based Analysis of 4,041 Patients. Annals of Surgical Oncology, 2008, 15, 500-507.	0.7	48
66	Retrospective Study of Palliative Radiotherapy in Newly Diagnosed Head and Neck Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 958-963.	0.4	48
67	Long term outcomes of stereotactic body radiation therapyÂfor hepatocellular carcinomaÂwithout macrovascular invasion. European Journal of Cancer, 2020, 134, 41-51.	1.3	46
68	Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. International Journal of Radiation Oncology Biology Physics, 2006, 65, 713-719.	0.4	45
69	Adjuvant Therapy for Resected Gastric Cancerâ€"Rapid, Yet Incomplete Adoption Following Results of Intergroup 0116 Trial. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1073-1080.	0.4	45
70	The prevalence and determinants of return to work in head and neck cancer survivors. Supportive Care in Cancer, 2019, 27, 539-546.	1.0	45
71	Outcomes toolbox for head and neck cancer research. Head and Neck, 2015, 37, 425-439.	0.9	43
72	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVIDâ€19 pandemic: The Princess Margaret experience and proposal. Cancer, 2020, 126, 3426-3437.	2.0	42

#	Article	IF	Citations
73	Rectal Motion in Patients Receiving Preoperative Radiotherapy for Carcinoma of the Rectum. International Journal of Radiation Oncology Biology Physics, 2011, 80, 97-102.	0.4	41
74	Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). International Journal of Radiation Oncology Biology Physics, 2017, 97, 678-686.	0.4	41
75	Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: Quality of life in a prospective phase I/II trial. Radiotherapy and Oncology, 2008, 87, 181-187.	0.3	40
76	Scoping review of the literature on shoulder impairments and disability after neck dissection. Head and Neck, 2014, 36, 299-308.	0.9	40
77	Truths and Myths About Radiotherapy for Verrucous Carcinoma of Larynx. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1110-1115.	0.4	39
78	Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience. Head and Neck, 2016, 38, E1102-9.	0.9	39
79	Assessing head and neck cancer patient preferences and expectations: A systematic review. Oral Oncology, 2016, 62, 44-53.	0.8	39
80	Results of radiotherapy for primary subglottic squamous cell carcinoma. International Journal of Radiation Oncology Biology Physics, 2002, 52, 1245-1250.	0.4	38
81	Predictors of Early Recurrence Prior to Planned Postoperative Radiation Therapy for Oral Cavity Squamous Cell Carcinoma and Outcomes Following Salvage Intensified Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 363-373.	0.4	38
82	A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy. Radiotherapy and Oncology, 2019, 131, 179-185.	0.3	38
83	Accuracy of ultrasound in localization of breast boost field. Radiotherapy and Oncology, 2004, 72, 61-66.	0.3	37
84	Morphologic and topographic radiologic features of human papillomavirusâ€related and –unrelated oropharyngeal carcinoma. Head and Neck, 2017, 39, 1524-1534.	0.9	37
85	Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT). International Journal of Radiation Oncology Biology Physics, 2018, 101, 900-909.	0.4	37
86	Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients. Oral Oncology, 2013, 49, 407-412.	0.8	36
87	"l didn't actually know there was such a thing as rehabâ€s survivor, family, and clinician perceptions of rehabilitation following treatment for head and neck cancer. Supportive Care in Cancer, 2016, 24, 1449-1453.	1.0	36
88	Quality of Life in a Prospective, Multicenter Phase 2 Trial of Neoadjuvant Full-Dose Gemcitabine, Oxaliplatin, and Radiation inÂPatients With Resectable or Borderline Resectable Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, 270-277.	0.4	35
89	Development of a diseaseâ€specific qualityâ€ofâ€life questionnaire for anterior and central skull base pathology—The skull base inventory. Laryngoscope, 2012, 122, 1933-1942.	1.1	33
90	Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer. Radiotherapy and Oncology, 2017, 124, 225-231.	0.3	33

#	Article	IF	CITATIONS
91	Evaluation of Quality of Life and Organ Function in Head and Neck Squamous Cell Carcinoma. Hematology/Oncology Clinics of North America, 2008, 22, 1239-1256.	0.9	32
92	Is Pilocarpine Effective in Preventing Radiation-Induced Xerostomia? A Systematic Review and Meta-analysis. International Journal of Radiation Oncology Biology Physics, 2016, 94, 503-511.	0.4	32
93	Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 847-856.	0.4	31
94	Work-related experiences of head and neck cancer survivors: an exploratory and descriptive qualitative study. Disability and Rehabilitation, 2018, 40, 1252-1258.	0.9	31
95	Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors. Frontiers in Oncology, 2020, 10, 930.	1.3	31
96	Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer. Head and Neck, 2015, 37, 655-661.	0.9	30
97	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. Radiotherapy and Oncology, 2020, 144, 13-22.	0.3	30
98	Clinical outcomes in patients with T4 laryngeal cancer treated with primary radiotherapy versus primary laryngectomy. Head and Neck, 2016, 38, E2035-40.	0.9	29
99	Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1127-1136.	0.4	28
100	A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. Radiotherapy and Oncology, 2008, 87, 173-180.	0.3	28
101	The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative. Journal of the National Cancer Institute, 2016, 108, djv391.	3.0	28
102	Informational Needs of Head and Neck Cancer Patients. Journal of Cancer Education, 2018, 33, 847-856.	0.6	28
103	A scoping review of rehabilitation interventions for survivors of head and neck cancer. Disability and Rehabilitation, 2019, 41, 2093-2107.	0.9	28
104	Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer, 2010, 116, 4023-4032.	2.0	27
105	Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 186-195.	0.4	27
106	Quality of life and utility in irradiated laryngeal cancer patients. International Journal of Radiation Oncology Biology Physics, 2000, 47, 875-881.	0.4	26
107	Lack of influence of intravenous contrast on head and neck IMRT dose distributions. Acta Oncol \tilde{A}^3 gica, 2008, 47, 90-94.	0.8	25
108	Quality of Life in Head and Neck Cancer: Where We Are, and Where We Are Going. International Journal of Radiation Oncology Biology Physics, 2017, 97, 662-666.	0.4	25

#	Article	IF	CITATIONS
109	Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire. Cancer, 2020, 126, 4042-4050.	2.0	25
110	Physical morbidity by surgical approach and tumor location in skull base surgery. Head and Neck, 2013, 35, 493-499.	0.9	24
111	Survey of computer use for health topics by patients with head and neck cancer. Head and Neck, 2005, 27, 8-14.	0.9	23
112	Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. Radiotherapy and Oncology, 2021, 154, 70-75.	0.3	23
113	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. Radiotherapy and Oncology, 2021, 165, 94-102.	0.3	22
114	Joint modeling of longitudinal health-related quality of life data and survival. Quality of Life Research, 2015, 24, 795-804.	1.5	21
115	Integrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists' perspectives. Quality of Life Research, 2015, 24, 1317-1325.	1.5	21
116	The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. Oncotarget, 2018, 9, 20439-20450.	0.8	21
117	The development and validation of a quality-of-life questionnaire for head and neck cancer patients with enteral feeding tubes: the QOL-EF. Supportive Care in Cancer, 2011, 19, 1175-1182.	1.0	20
118	Phase I trial of radiation therapy and sorafenib in unresectable liver metastases. Radiotherapy and Oncology, 2017, 123, 234-239.	0.3	20
119	Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311) Journal of Clinical Oncology, 2021, 39, 6010-6010.	0.8	20
120	Quality of life instruments for skull base pathology: Systematic review and methodologic appraisal. Head and Neck, 2013, 35, 1221-1231.	0.9	19
121	Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 858-867.	0.4	19
122	Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 368.	1.2	19
123	Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiotherapy and Oncology, 2021, 156, 120-126.	0.3	19
124	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). British Journal of Cancer, 2021, 124, 1543-1551.	2.9	19
125	Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors. PLoS ONE, 2016, 11, e0152944.	1.1	19
126	Quality of life in patients with Kâ€ <i>RAS</i> wildâ€ŧype colorectal cancer. Cancer, 2014, 120, 181-189.	2.0	18

#	Article	IF	Citations
127	Assessment of the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire for use in patients after neck dissection for head and neck cancer. Head and Neck, 2015, 37, 234-242.	0.9	18
128	Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). European Journal of Cancer, 2017, 72, 192-199.	1.3	18
129	Patient-Reported Symptoms for Esophageal Cancer Patients Undergoing Curative Intent Treatment. Annals of Thoracic Surgery, 2020, 109, 367-374.	0.7	18
130	Partial Laryngeal IMRT for T2NO Glottic Cancer: Impact of Image Guidance and Radiation Therapy Intensification. International Journal of Radiation Oncology Biology Physics, 2018, 102, 941-949.	0.4	17
131	Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial Journal of Clinical Oncology, 2015, 33, 6000-6000.	0.8	17
132	Randomized Trial Comparing Radiologic Pigtail Gastrostomy and Peroral Image-Guided Gastrostomy: Intra- and Postprocedural Pain, Radiation Exposure, Complications, and Quality of Life. Journal of Vascular and Interventional Radiology, 2015, 26, 1680-1686.	0.2	15
133	Outcome following radiotherapy for head and neck basal cell carcinoma with â€~aggressive' features. Oral Oncology, 2017, 72, 157-164.	0.8	15
134	The Prevalence and Determinants of Return to Work in Nasopharyngeal Carcinoma Survivors. International Journal of Radiation Oncology Biology Physics, 2020, 106, 134-145.	0.4	15
135	Development and preliminary evaluation of a rehabilitation consult for survivors of head and neck cancer: an intervention mapping protocol. Implementation Science, 2015, 10, 6.	2.5	14
136	Impact of cisplatin dose and smoking pack-years in human papillomavirus–positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. European Journal of Cancer, 2019, 118, 112-120.	1.3	14
137	E-Mail Communication Practices and Preferences Among Patients and Providers in a Large Comprehensive Cancer Center. Journal of Oncology Practice, 2016, 12, 676-684.	2.5	13
138	Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy. Practical Radiation Oncology, 2017, 7, e331-e337.	1.1	13
139	Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 587-599.	0.7	12
140	Partner's survivorship care needs: An analysis in head and neck cancer patients. Oral Oncology, 2017, 71, 113-121.	0.8	12
141	Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. Oral Oncology, 2021, 114, 105167.	0.8	11
142	Early stage hepatocellular carcinoma treated with stereotactic body radiation therapy: A pooled analysis from two North American institutions Journal of Clinical Oncology, 2019, 37, 350-350.	0.8	11
143	Impact of neoadjuvant radiation on margins for non–squamous cell carcinoma sinonasal malignancies. Laryngoscope, 2018, 128, 2796-2803.	1.1	10
144	<scp>Outâ€ofâ€pocket</scp> costs associated with head and neck cancer treatment. Cancer Reports, 2022, 5, e1528.	0.6	10

#	Article	IF	CITATIONS
145	Long-Term Quality of Life of Retroperitoneal Sarcoma Patients Treated with Pre-Operative Radiotherapy and Surgery. Cureus, 2017, 9, e1764.	0.2	10
146	Clinical presentation and outcome of human papillomavirusâ€positive nasopharyngeal carcinoma in a North American cohort. Cancer, 2022, 128, 2908-2921.	2.0	10
147	Response rates for mailout surveyâ€driven studies in patients with head and neck cancer. Head and Neck, 2010, 32, 1585-1591.	0.9	9
148	Prevalence, prognosis, and treatment implications of retropharyngeal nodes in unknown primary head and neck carcinoma. Oral Oncology, 2018, 82, 162-167.	0.8	9
149	Pre―and Postâ€Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. Laryngoscope, 2021, 131, E1162-E1171.	1.1	9
150	Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer. Oncology, 2021, 99, 49-56.	0.9	9
151	Making better use of existing cancer data: Patient Reported Outcomes and Behavioural Evidence: a new international initiative. European Journal of Cancer Care, 2009, 18, 105-107.	0.7	8
152	A Randomized Controlled Trial of Lorazepam to Reduce Liver Motion in Patients Receiving Upper Abdominal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, 881-887.	0.4	8
153	Evaluation of shoulder disability questionnaires used for the assessment of shoulder disability after neck dissection for head and neck cancer. Head and Neck, 2014, 36, 1453-1458.	0.9	8
154	Validation of distant metastases risk-groups in oral cavity squamous cell carcinoma patients treated with postoperative intensity-modulated radiotherapy. Radiotherapy and Oncology, 2019, 134, 10-16.	0.3	8
155	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. Oral Oncology, 2020, 105, 104666.	0.8	8
156	Pre-treatment psychoeducational intervention and outcomes in head and neck cancer patients undergoing radiotherapy. Supportive Care in Cancer, 2021, 29, 1643-1652.	1.0	8
157	Treatment outcomes and survival following definitive (chemo)radiotherapy in <scp>HPV</scp> â€positive oropharynx cancer: Largeâ€scale comparison of <scp>DAHANCA</scp> vs <scp>PMH</scp> cohorts. International Journal of Cancer, 2022, 150, 1329-1340.	2.3	8
158	Psychometric properties of patient-reported outcome measures for dysphagia in head and neck cancer: a systematic review protocol using COSMIN methodology. Systematic Reviews, 2022, 11, 27.	2.5	8
159	Assessment of nonrespiratory stomach motion in healthy volunteers in fasting and postprandial states. Practical Radiation Oncology, 2014, 4, 288-293.	1.1	7
160	Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (â^') locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) Journal of Clinical Oncology, 2015, 33, 6020-6020.	0.8	7
161	Outcome following IMRT for T2 glottic cancer: the potential impact of image-guidance protocols on local control. Journal of Radiation Oncology, 2014, 3, 267-275.	0.7	6
162	In Regard to Yerramilli etÂal's "Palliative Radiotherapy for Oncologic Emergencies in the Setting of COVID-19: Approaches to Balancing Risks and Benefits― Advances in Radiation Oncology, 2020, 5, 595-596.	0.6	6

#	Article	IF	Citations
163	E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process Journal of Clinical Oncology, 2016, 34, 6054-6054.	0.8	6
164	Extra-pulmonary small cell carcinoma in the head and neck setting: The role of prophylactic cranial irradiation. Oral Oncology, 2015, 51, e57-e59.	0.8	5
165	Quality of Life and Value Considerations in Head and Neck Proton Beam Therapy: The Holy Grail at Last, or the Quest Continues?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 40-42.	0.4	5
166	The "rocky treatment course― identifying a high-risk subgroup of head and neck cancer patients for supportive interventions. Supportive Care in Cancer, 2017, 25, 719-727.	1.0	5
167	Evaluation of a rehabilitation planning consult for survivors of head and neck cancer. Head and Neck, 2018, 40, 1415-1424.	0.9	5
168	Readmission rates following esophageal cancer resection are similar at regionalized and non-regionalized centers: AApopulation-based cohort study. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 934-942.e2.	0.4	5
169	Presence and duration of feeding tube in a 5â€year cohort of patients with head and neck cancer treated with curative i <scp>ntensityâ€modulated</scp> radiation therapy. Head and Neck, 2021, 43, 1610-1620.	0.9	5
170	Role of the oral and gut microbiota as a biomarker in locoregionally advanced oropharyngeal squamous cell carcinoma (ROMA LA-OPSCC) Journal of Clinical Oncology, 2019, 37, 6045-6045.	0.8	5
171	Facing head and neck cancer deaths head on: Lessons for survival. Cancer, 2014, 120, 1446-1449.	2.0	4
172	Retrospective assessment of patterns of recurrence relative to radiotherapy volumes for adjuvant conformal chemoradiotherapy in gastric cancer. Gastric Cancer, 2016, 19, 887-893.	2.7	4
173	Sexual satisfaction in nasopharyngeal carcinoma survivors: Rates and determinants. Oral Oncology, 2020, 109, 104865.	0.8	4
174	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. Radiotherapy and Oncology, 2021, 157, 255-262.	0.3	4
175	Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario. Canadian Liver Journal, 2021, 4, 257-274.	0.3	4
176	Outcome and treatment toxicity in east-indian versus white-canadian patients with oral cavity cancer following postoperative (chemo-)radiotherapy delivered under similar multidisciplinary care: A propensity-matched cohort study. Oral Oncology, 2021, 120, 105419.	0.8	4
177	Outcome and toxicity of postoperative short course adjuvant radiation and chemotherapy following resection of adenocarcinoma of the rectum. Acta Oncol \tilde{A}^3 gica, 2004, 43, 567-570.	0.8	3
178	Improving Head and Neck Cancer Outcomes: Technology, Used Wisely. International Journal of Radiation Oncology Biology Physics, 2016, 96, 489-492.	0.4	3
179	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 994-1002.	0.4	3
180	Regional Recurrences and Hyams Grade in Esthesioneuroblastoma. Journal of Neurological Surgery, Part B: Skull Base, 2021, 82, 608-614.	0.4	3

#	Article	IF	CITATIONS
181	Canadian Perspectives on Radiation Oncologist Workforce Planning and the Job Market. International Journal of Radiation Oncology Biology Physics, 2022, 112, 282-284.	0.4	3
182	Technical challenges of sparing infrahyoid swallowing organs at risk in oropharynx squamous cell cancer treated with IMRT. Medical Dosimetry, 2014, 39, 146-151.	0.4	2
183	Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy. Oral Oncology, 2019, 97, 124-130.	0.8	2
184	Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma. Radiotherapy and Oncology, 2021, 156, 95-101.	0.3	2
185	"lt's good for the soul:―Perceptions of a formal junior faculty mentorship program at a large academic cancer centre. Radiotherapy and Oncology, 2021, 162, 119-123.	0.3	2
186	A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6) Journal of Clinical Oncology, 2012, 30, TPS5600-TPS5600.	0.8	2
187	Prospective evaluation of quality of life (QOL) during a phase I/II study of adjuvant chemotherapy with image-guided high-precision radiotherapy for completely resected gastric cancer Journal of Clinical Oncology, 2016, 34, 164-164.	0.8	2
188	Quality of Life in Head and Neck Cancer Patients. , 2016, , 809-820.		2
189	Employment Outcomes for Canadian Radiation Oncology Graduates: 2020 Assessment and Longitudinal Trends. Advances in Radiation Oncology, 2022, 7, 100915.	0.6	2
190	In reply to Dr. Cheng. International Journal of Radiation Oncology Biology Physics, 2006, 65, 311-312.	0.4	1
191	The Effect of Registration Volume Extent on Residual Errors Assessed Using Cone-Beam Computed Tomography in Radiation Treatment of Head and Neck Cancer. Journal of Medical Imaging and Radiation Sciences, 2012, 43, 95-102.	0.2	1
192	Response to Letter to the Editor with Reference to article "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure― Oral Oncology, 2013, 49, e19.	0.8	1
193	Gastric cancer recurrence after resection and adjuvant chemoradiation. Journal of Radiation Oncology, 2015, 4, 79-85.	0.7	1
194	Shortâ€ŧerm and longâ€ŧerm unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma. Head and Neck, 2021, 43, 456-466.	0.9	1
195	Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02 Journal of Clinical Oncology, 2012, 30, 5571-5571.	0.8	1
196	An international study of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different cancer sites Journal of Clinical Oncology, 2012, 30, 6002-6002.	0.8	1
197	Partner's survivorship care needs: Multivariable analysis in head and neck cancer patients Journal of Clinical Oncology, 2016, 34, 120-120.	0.8	1
198	Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer Journal of Clinical Oncology, 2017, 35, 4053-4053.	0.8	1

#	Article	IF	Citations
199	Development and validation of a prediction-score model for distant metastases in major salivary gland carcinoma Journal of Clinical Oncology, 2019, 37, 6085-6085.	0.8	1
200	Development and Validation of an Oral Cavity Cancer Outcomes Prediction Score Incorporating Patient-Derived Xenograft Engraftment. JAMA Otolaryngology - Head and Neck Surgery, 2022, , .	1.2	1
201	Locoregional control remains a critical issue in gastric cancer. Gastric Cancer, 2008, 11, 64-65.	2.7	0
202	CLINICAL USE OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM CANCER CLINICAL TRIALS: PRELIMINARY RESULTS FROM A SURVEY OF ONCOLOGISTS. Journal of Epidemiology and Community Health, 2013, 67, e2.17-e2.	2.0	0
203	No evidence for improved TORS post-treatment feeding tube dependency rate relative to standard therapy in early stage oropharyngeal cancer. Oral Oncology, 2015, 51, e67.	0.8	0
204	Changes Experienced in Quality of Life for Skull Base Surgical Patients: A Qualitative Case Study. Journal of Neurological Surgery, Part B: Skull Base, 2015, 76, 129-144.	0.4	0
205	Reply to N. Osazuwa-Peters et al. Journal of Clinical Oncology, 2016, 34, 1152-1152.	0.8	0
206	Variability in Steroid Prophylaxis for Radiation-Induced Pain Flare: Practice of Canadian Radiation Oncologists. Journal of Palliative Medicine, 2021, 24, 965-966.	0.6	0
207	Have We Tipped the Balance in HPV-Associated Oropharyngeal Cancer?: The Patient-Experience Side of the De-Escalation Balance Scale. International Journal of Radiation Oncology Biology Physics, 2021, 111, 887-889.	0.4	0
208	Does change in health-related quality of life (HRQoL) score predict survival? Analysis of a lung cancer RCT Journal of Clinical Oncology, 2012, 30, 7607-7607.	0.8	0
209	Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma Journal of Clinical Oncology, 2013, 31, 226-226.	0.8	0
210	Outcomes following stereotactic body radiotherapy for patients with Child-Pugh B/C hepatocellular carcinoma Journal of Clinical Oncology, 2013, 31, 167-167.	0.8	0
211	Email communication practices and preferences among patients and providers in a large comprehensive cancer center Journal of Clinical Oncology, 2015, 33, 6519-6519.	0.8	0
212	Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248) Journal of Clinical Oncology, 2015, 33,	0.8	0
213	Patient recruitment in an oligometastases trial: experience from a phase II study of 5 fraction stereotactic body radiation therapy (SBRT) Journal of Clinical Oncology, 2016, 34, e14050-e14050.	0.8	0
214	Clinical relevance of lymph node ratio in resected oral cavity squamous cell carcinoma in patients with N2 disease Journal of Clinical Oncology, 2016, 34, 6019-6019.	0.8	0
215	Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre Journal of Clinical Oncology, 2017, 35, 189-189.	0.8	0
216	Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre Journal of Clinical Oncology, 2017, 35, 126-126.	0.8	0

#	Article	IF	CITATIONS
217	Outcomes for patients â%¥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre Journal of Clinical Oncology, 2017, 35, 10037-10037.	0.8	O
218	Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion Journal of Clinical Oncology, 2019, 37, 428-428.	0.8	0
219	Impact of adjuvant chemotherapy and cumulative cisplatin dose in locally advanced nasopharyngeal carcinoma (LA-NPC) treated with definitive chemoradiotherapy Journal of Clinical Oncology, 2019, 37, 6046-6046.	0.8	0
220	Variation in treatment patterns and outcomes for resected esophageal cancer at designated thoracic surgery centers Journal of Clinical Oncology, 2020, 38, 343-343.	0.8	0
221	Short and Simple Palliative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 112, 583-584.	0.4	0
222	Impact of the COVID-19 Pandemic on Canadian Radiation Oncology Practices. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	0
223	Osteoradionecrosis in head and neck cancer patients: Risk factors and comparison of grading systems Journal of Clinical Oncology, 2022, 40, e18057-e18057.	0.8	0
224	Prognostic factors in sinonasal cancers: A multicenter pooled analysis Journal of Clinical Oncology, 2022, 40, 6092-6092.	0.8	0